A detailed history of Wells Fargo & Company transactions in Pep Gen Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 5,052 shares of PEPG stock, worth $21,723. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,052
Previous 5,184 2.55%
Holding current value
$21,723
Previous $82,000 47.56%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$7.75 - $18.55 $1,023 - $2,448
-132 Reduced 2.55%
5,052 $43,000
Q2 2024

Aug 13, 2024

BUY
$10.54 - $18.14 $18,002 - $30,983
1,708 Added 49.14%
5,184 $82,000
Q1 2024

May 10, 2024

BUY
$6.63 - $17.3 $3,328 - $8,684
502 Added 16.88%
3,476 $51,000
Q4 2023

Feb 09, 2024

BUY
$3.86 - $7.96 $2,339 - $4,823
606 Added 25.59%
2,974 $20,000
Q3 2023

Nov 13, 2023

SELL
$5.0 - $9.09 $8,300 - $15,089
-1,660 Reduced 41.21%
2,368 $12,000
Q2 2023

Aug 15, 2023

BUY
$8.94 - $16.39 $11,014 - $20,192
1,232 Added 44.06%
4,028 $36,000
Q1 2023

May 12, 2023

BUY
$11.44 - $17.7 $31,986 - $49,489
2,796 New
2,796 $34,000
Q3 2022

Nov 14, 2022

SELL
$4.86 - $12.75 $393 - $1,032
-81 Reduced 60.45%
53 $0
Q2 2022

Aug 12, 2022

BUY
$9.0 - $12.89 $1,206 - $1,727
134 New
134 $1,000

Others Institutions Holding PEPG

About PepGen Inc.


  • Ticker PEPG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,631,900
  • Market Cap $102M
  • Description
  • PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is a...
More about PEPG
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.